附子干姜合用丙磺舒、兰索拉唑对NOS抑制型高血压模型小鼠影响观察

目的 ：研究附子干姜合用丙磺舒、兰索拉唑对一氧化氮合酶（NOs）抑制型高血压模型小鼠的影响,并初步探讨其作用机制。方法：将雄性ICR小鼠随机分为空白对照组（C组）、左旋N-硝基精氨酸（L广NNA）模型组（M组）、L—NNA＋附子干姜组（FG组）、L-NNA＋丙磺舒组（B组）、L—NNA＋兰索拉唑组（L组）、L—NNA＋附子干姜＋丙磺舒组（FG＋B组）、L—NNA＋兰索拉唑＋丙磺舒组（L＋B组）、L-NNA＋附子干姜＋兰索拉唑＋丙磺舒组（FG＋L＋B组）。各组分别给予0．5％羧甲基纤维素钠（CMC-Na）溶液、L—NNA、L—NNA＋附子干姜水煎液3g／kg、L—NNA＋丙磺舒360mg／kg、L-NNA＋兰索拉唑30mg／kg、L-NNA＋附子干姜水煎液3g／kg＋丙磺舒360mg／kg、L—NNA＋兰索拉唑组30mg／kg＋丙磺舒组360mg／kg,L-NNA＋附子干姜水煎液3g／kg＋丙磺舒360mg／kg＋兰索拉唑30mg／kg。持续灌胃给药10天后测定各组小鼠的血压,检测血清、心、肝、肾和胃组织中的一氧化氮（NO）和丙二醛（MDA）含量。结果：与C组相比,M组、B组、L组和L＋B组血压显著升高（P〈0．01,P〈0．05,P〈0．05）,M组和B组大鼠的血清和心、肝、肾、胃中的N0含量下降,MDA含量升高（P〈0．01或P〈0．05）。与模型组相比,FG组、FG＋B组、FG＋B＋L组小鼠的血压和生化指标均有所改善（P〈0．01或P〈0．05）,其中FG＋B组死亡率最低,FG＋B＋L组其次。结论：FG组、FG＋B组、FG＋B＋L组药物均能升高NOS抑制型高血压小鼠的NO含量,降低MDA含量,从而产生降压、降低组织氧化损伤的作用,其中FG＋B＋L组小鼠更趋近于正常水平。     

兰索拉唑联合莫沙比利治疗68例胃食管反流病的疗效观察

[目的]结合临床实践经验,探讨兰索拉唑联合莫沙比利治疗胃食管反流病的临床疗效。[方法]采用对照研究,经患者知情同意,将其分为对照组(34例)与观察组(34例),治疗前2周,所有病例内均未服用H2受体拮抗剂和质子泵抑制剂。对照组给予兰索拉唑(30mg),早晨空腹服用,每日1次。观察组采用联合用药,在对照组的基础上给予莫沙比利(5mg)餐前半小时服用,每日3次。所有患者治疗6周后复查胃镜,比较治疗效果,探讨兰索拉唑联合莫沙比利治疗胃食管反流病的临床疗效。[结果]治疗前后,各组患者差异有统计学意义(P﹤0.05),治疗6周后,观察者患者炎症程度明显低于对照组,差异有统计学意义(P﹤0.05)。观察组总有效率明显高于对照组,差异有统计学意义(χ2=13.29,P﹤0.05),观察组有3例患者出现不良反应(8.82),其中稀便1例,头晕1例,倦怠1例。对照组有4例患者出现不良反应(11.76),其中,稀便1例,头晕1例,口干1例,恶心1例。两组不良反应发生率差异无统计学意义(P﹥0.05)。[结论]采用兰索拉唑联合莫沙比利治疗反流性食管病疗效显著,值得临床推广应用。     

兰索拉唑联合莫沙必利治疗老年胃食管反流病临床分析

目的：探究兰索拉唑联合莫沙必利治疗老年胃食管反流病临床疗效。方法整群选取该院2014年6月—2015年9月期间所收治的老年胃食管反流患者78例,将其随机分为两组,对照组和观察组各39例。给予对照组兰索拉唑治疗,观察组在此基础上加服莫沙必利,比较两组患者治疗后的总有效率和不良反应率。结果观察组在使用兰索拉唑联合莫沙必利治疗后总有效率为92.31%,高于对照组的79.48%,差异具有统计学意义(P<0.05）;观察组不良反应率为7.68%,低于对照组的15.36%,差异具有统计学意义(P<0.05）。结论兰索拉唑联合莫沙必利治疗老年胃食管反流疾病,临床有效率高,不良反应率低,可以较好的改善患者身体机能,提升患者生活质量。     

探讨胃镜下兰索拉唑与凝血酶联合治疗消化性溃疡出血的临床疗效

目的：探讨胃镜下兰索拉唑与凝血酶联合治疗消化性溃疡出血的临床疗效,并为临床开展高效、科学的治疗方案提供指导。方法选取平江县第一人民医院2010年4月～2012年8月收治的104例消化性溃疡伴出血患者为研究对象,利用随机数字表法均分为研究组和对照组（n=52）。对照组给予冰冻生理盐水加去甲肾上腺素联合治疗,研究组给予兰索拉唑与凝血酶联合治疗。记录2组患者在5 min、8 h和24 h内有效止血例数及再出血发生率,并进行比较。结果研究组患者在5 min、8 h和24 h内有效止血分别为38例（73.1%）、12例（23.1%）、2例（3.85%）,而对照组分别为17例（32.7%）、12例（23.1%）、10例（19.2%）,2组有效止血率比较,差异有统计学意义（P〈0.05）。研究组再出血为6例（11.5%）,对照组为17例（32.7%）,2组比较,差异有统计学意义（P〈0.05）。结论对于消化性溃疡出血患者而言,给予兰索拉唑与凝血酶联合治疗可以提高患者的有效止血率,降低再出血发生率,取得较为满意的临床效果。     

兰索拉唑肠溶片人体生物利用度及生物等效性研究

目的:研究兰索拉唑肠溶片人体生物利用度及生物等效性。方法:22例健康志愿受试者交叉口服兰索拉唑肠溶片和兰索拉唑胶囊剂各30 mg,以非那西丁为内标,HPLC-UV法测定血浆中兰索拉唑浓度。结果与结论:健康志愿者口服两种制剂各30 mg后,Cm ax分别为(1 057.26±230.42)ng.mL-1和(1 336.35±288.88)ng.mL-1;tm ax分别为(2.6±0.6)h和(2.1±0.6)h;t1/2分别为(1.85±0.28)h和(1.75±0.34)h;AUC0-12分别为(3 565.34±1 233.03)h.ng.mL-1和(3 951.22±1 375.82)h.ng.mL-1。各参数经统计学配对t检验,均无显著性差异(P>0.05)。兰索拉唑肠溶片与兰索拉唑胶囊剂在健康志愿者体内的药动学参数相似。     

HPLC法测定注射用兰索拉唑中主药及有关物质的含量

目的:建立以高效液相色谱法测定注射用兰索拉唑中主药及有关物质含量的方法。方法:色谱柱为Shim-packC18,流动相为甲醇-水-三乙胺-磷酸(620∶380∶5∶1·5),流速为1mL·min-1,检测波长为284nm,进样量为20μL。结果:兰索拉唑检测浓度的线性范围为16~320μg·mL-l(r=0·9999);平均回收率为100·0%(RSD=1·08%,n=9);有关物质含量均为0·147%。结论:该方法简便、快速、准确、重现性好,适用于该制剂的质量控制。     

Reversible lansoprazole-induced interstitial lung disease showing improvement after drug cessation.

Lansoprazole is an acid proton-pump inhibiting drug that is used for the treatment of duodenal or gastric ulcers, H. pylori infection, gastroesophageal reflux disease or Zollinger-Ellison syndrome. Although lansoprazole is well known for its gastrointestinal and dermatologic adverse effects, mild pulmonary symptoms are also known to develop from taking this drug. There have been no reports about lansoprazole-induced interstitial lung disease. We report here a case of lansoprazole-induced interstitial lung disease that developed in a 66-year-old man.     

Determination of Lansoprazole by Direct Injection of Plasma and High Performance Liquid Chromatography with Column Switching

建立了用柱切换测定血浆中兰索拉唑的方法。血样用蒸馏水简单稀释后注入填充ＬｉＣｈｒｏｍｐｒｅｐＲＰ２（２５～４０μｍ）的预柱上。用蒸馏水冲洗出血浆中蛋白质和其它极性成分。切换后，浓缩在预柱上的兰索拉唑被流动相甲醇０２ｍｏｌ·Ｌ１醋酸铵（６５：３５）反冲到分析柱ＳｈｉｍｐａｃｋＣＬＣＯＤＳ上进行分析。预柱用净化液进行消除和再生。本法有很好的精密度和回收率，检测限为０００５ｍｇ·Ｌ１，日内和日间测定相对标准差小于２５％和５３％。此分析方法已成功地用于测定自愿受试者的兰索拉唑药代动力学     

Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough： A comparison between two different daily doses of lansoprazole

AIM:To compare two different daily doses oflansoprazole given for 12 weeks and to assess the roleof gastrointestinal (GI) investigations as criteria forselecting patients.METHODS:Out of 45 patients referred for unexplainedchronic persistent cough,36 had at least one of theGI investigations (endoscopy,24-h esophageal pH-metry and a 4-week trial of proton pump inhibitor (PPI)therapy) positive and were randomly assigned to receiveeither 30 mg lansoprazole o.d.or 30 mg lansoprazoleb.i.d,for 12 weeks.Symptoms were evaluated atbaseline (visit 1) after the PPI test (visit 2) and after the12-week lansoprazole treatment period (visit 3).RESULTS:Thirty-five patients completed the studyprotocol.Twenty-one patients (60.0%) reportedcomplete relief from their cough with no differencebetween the two treatment groups (58.8% and 61.1%had no cough in 30 mg lansoprazole and 60 mglansoprazole groups,respectively).More than 80% ofthe patients who had complete relief from their cough atthe end of the treatment showed a positive response tothe PPI test.CONCLUSION:Twelve weeks of lansoprazole treatmenteven at a standard daily dose,is effective in patientswith chronic persistent cough.A positive response to aninitial PPI test seems to be the best criterion for selectingpatients who respond to therapy.     

Long-Term Efficacy of Lansoprazole in Preventing Relapse of Erosive Reflux Esophagitis

In a phase III study of lansoprazole treatment, patients with healed or unhealed erosive esophagitis entered a titrated open-label treatment period and received lansoprazole for ≤6 years to assess long-term maintenance therapy. Doses were adjusted depending on symptom response. Endoscopy was performed yearly. One hundred ninety-five subjects received lansoprazole for <1 to 72 months; most received daily doses of ≤30 mg. Lansoprazole maintained erosive esophagitis remission in 75% of subjects receiving treatment for ≤72 months, with 39 subjects experiencing 50 recurrences. Most subjects (94–95%) had no or mild symptoms of day or night heartburn at study end, and 77% were asymptomatic at first erosive esophagitis recurrence. The most common treatment-related adverse events included diarrhea (10%), headache (8%), and abdominal pain (6%), and were mild or moderate in severity. Long-term lansoprazole is effective and well tolerated when used to maintain erosive esophagitis remission for ≤6 years.